Clinical study of dendritic cell vaccine combined with transarterial embolization for patients with hepatocellular carcinoma

Clinical study of dendritic cell vaccine combined with transarterial embolization for patients with hepatocellular carcinoma - Dendritic cell vaccine with transarterial embolization for HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012702

Enrollment

Registered

2013-12-26

Start date

2013-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Intraarterial infusion of dendritic cell vaccine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Proven HCC patients (2) Karnofsky Performance Status 70 %= or < (3) Liver damage(Child-Pugh) A or B (4) Preserved bone marrow function (5) Preserved renal function (6) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Severe concurrent disease 2) HIV antibody and/or HTLV-1 antibody positive 3) No other malignancy 4) No splenectomy 5) No Allograft transplantation 6) No immunosuppressive treatment 7) No treatment for HCC within 4 weeks 8) Pregnant and lactating females 9) Inappropriate for entry onto this study in the judgment of the investigator

Design outcomes

Primary

Measure	Time frame
Safety of the treatment	—

Countries

Japan

Contacts

Public ContactTomoyuki Nemoto

Faculty of Medical Sciences, University of Fukui Second Department of Internal Medicine

nemotot@u-fukui.ac.jp0776-61-8351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026